Kerry Holford
Stock Analyst at Berenberg Bank
(3.87)
# 1,933
Out of 4,707 analysts
244
Total ratings
56.6%
Success rate
8.4%
Average return
Main Sectors:
Stocks Rated by Kerry Holford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Maintained: Hold | 2,000p | 1,797p | +11.33% | 50 | Aug 17, 2026 | |
| LLY Eli Lilly and Company | Maintained: Hold | $1,135 → $1,220 | $1,123.91 | +8.55% | 32 | Aug 13, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Downgraded: Hold | kr 325.00 → kr 305.00 | kr 292.00 | +4.45% | 42 | Aug 12, 2026 | |
| NVO Novo Nordisk | Downgraded: Hold | $47 | $45.16 | +4.07% | 8 | Aug 11, 2026 | |
| PFE Pfizer | Maintained: Hold | $25 | $27.79 | -10.04% | 31 | Aug 5, 2026 | |
| NVS Novartis AG | Maintained: Hold | $141 → $147 | $137.70 | +6.75% | 9 | Jul 27, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 92.00 → CHF 120.00 | CHF 111.80 | +7.33% | 41 | Jul 27, 2026 | |
| LON: 0NZT UCB SA | Maintained: Buy | €130.00 → €305.00 | €206.95 | +47.38% | 3 | Jul 2, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | $128 → $47 | $46.61 | +0.18% | 4 | Jun 16, 2026 | |
| GSK GSK plc | Maintained: Hold | $41 → $43 | $48.54 | -11.41% | 14 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €105.00 → €120.00 | €74.70 | n/a | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €1.60 | €1.68 | n/a | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $65 → $60 | $101.69 | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 100p | 42p | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €150.00 | €134.60 | n/a | 1 | Apr 16, 2021 |
GSK plc
Aug 17, 2026
Maintained: Hold
Price Target: 2,000p
Current: 1,797p
Upside: +11.33%
Eli Lilly and Company
Aug 13, 2026
Maintained: Hold
Price Target: $1,135 → $1,220
Current: $1,123.91
Upside: +8.55%
Novo Nordisk A/S
Aug 12, 2026
Downgraded: Hold
Price Target: kr 325.00 → kr 305.00
Current: kr 292.00
Upside: +4.45%
Novo Nordisk
Aug 11, 2026
Downgraded: Hold
Price Target: $47
Current: $45.16
Upside: +4.07%
Pfizer
Aug 5, 2026
Maintained: Hold
Price Target: $25
Current: $27.79
Upside: -10.04%
Novartis AG
Jul 27, 2026
Maintained: Hold
Price Target: $141 → $147
Current: $137.70
Upside: +6.75%
Novartis AG
Jul 27, 2026
Maintained: Hold
Price Target: CHF 92.00 → CHF 120.00
Current: CHF 111.80
Upside: +7.33%
UCB SA
Jul 2, 2026
Maintained: Buy
Price Target: €130.00 → €305.00
Current: €206.95
Upside: +47.38%
Zealand Pharma A/S
Jun 16, 2026
Downgraded: Hold
Price Target: $128 → $47
Current: $46.61
Upside: +0.18%
GSK plc
Nov 25, 2025
Maintained: Hold
Price Target: $41 → $43
Current: $48.54
Upside: -11.41%
May 16, 2025
Maintained: Buy
Price Target: €105.00 → €120.00
Current: €74.70
Upside: n/a
Apr 1, 2025
Maintained: Hold
Price Target: €1.60
Current: €1.68
Upside: n/a
Mar 24, 2025
Maintained: Hold
Price Target: $65 → $60
Current: $101.69
Upside: n/a
Mar 24, 2025
Maintained: Buy
Price Target: 100p
Current: 42p
Upside: n/a
Apr 16, 2021
Maintained: Hold
Price Target: €150.00
Current: €134.60
Upside: n/a